Cost-effectiveness of pregabalin versus venlafaxine in the treatment of generalized anxiety disorder: Findings from a Spanish perspective

European Journal of Health Economics

Volumn 11, Issue 1, 2010, Pages 35-44

  Vera Llonch, Montserrat ^a   Dukes, Ellen ^b   Rejas, Javier ^b   Sofrygin, Oleg ^a   Mychaskiw, Marko ^b   Oster, Gerry ^a  

^a POLICY ANALYSIS INC PAI   (United States)

^b PFIZER INC   (United States)

Author keywords

Cost effectiveness; Generalized anxiety disorder; Models economics; Pregabalin; Venlafaxine

Indexed keywords

PAROXETINE; PREGABALIN; UNCLASSIFIED DRUG; VANDRAL RETARD; VENLAFAXINE;

ARTICLE; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; DRUG COST; DRUG EFFICACY; GENERALIZED ANXIETY DISORDER; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEALTH SERVICE; HUMAN; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; SCORING SYSTEM; SENSITIVITY ANALYSIS; TREATMENT OUTCOME;

ANTICONVULSANTS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANXIETY DISORDERS; CONFIDENCE INTERVALS; COST-BENEFIT ANALYSIS; CYCLOHEXANOLS; DELAYED-ACTION PREPARATIONS; ECONOMICS, PHARMACEUTICAL; GAMMA-AMINOBUTYRIC ACID; HUMANS; MODELS, ECONOMIC; MODELS, STATISTICAL; MONTE CARLO METHOD; PSYCHIATRIC STATUS RATING SCALES; PSYCHOMETRICS; QUALITY-ADJUSTED LIFE YEARS; SPAIN; TREATMENT OUTCOME;

EID: 76649091257     PISSN: 16187598     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10198-009-0160-7     Document Type: Article

References (33)

1. HU Wittchen RC Kessler K Beesdo, et al. 2002 Generalized anxiety and depression in primary care: prevalence, recognition, and management J. Clin. Psychiatr. 63 Suppl. 8 24 34
2. R Jenkins G Lewis P Bebbington, et al. 1997 The National Psychiatric Morbidity surveys of Great Britain-initial findings from the household survey Psychol. Med. 27 4 775 789 10.1017/S0033291797005308 10.1017/S0033291797005308 (Pubitemid 27332165)
3. R Lieb E Becker C Altamura 2005 The epidemiology of generalized anxiety disorder in Europe Eur. Neuropsychopharmacol. 15 4 445 452 10.1016/j.euroneuro. 2005.04.010 10.1016/j.euroneuro.2005.04.010 (Pubitemid 40943548)
4. RC Kessler PS Wang 2008 The descriptive epidemiology of commonly occurring mental disorders in the United States Annu. Rev. Public Health 29 115 129 10.1146/annurev.publhealth.29.020907.090847 10.1146/annurev.publhealth.29. 020907.090847 (Pubitemid 351600402)
5. W Katon M von Korff E Lin, et al. 1990 Distressed high utilizers of medical care: DMS-III-R diagnoses and treatment needs Gen. Hosp. Psychiatr. 12 6 35 62 10.1016/0163-8343(90)90002-T 10.1016/0163-8343(90)90002-T (Pubitemid 20359656)
6. BL Kennedy JJ Schwab 1997 Utilization of medical specialists by anxiety disorder patients Psychosomatics 38 2 109 112
7. DL Hoffman E Dukes HU Wittchen 2008 Human and economic burden of generalized anxiety disorder Depress. Anxiety 25 1 72 90 10.1002/da.20257 10.1002/da.20257 (Pubitemid 351213928)
8. K Rickels R Downing E Schweizer H Hassman 1993 Antidepressants for the treatment of generalized anxiety disorder: a placebo-controlled comparison of imipramine, trazodone, and diazepam Arch. Gen. Psychiatr. 50 11 884 895
9. G Fricchione 2004 Generalized anxiety disorder N. Engl. J. Med. 351 7 675 682 10.1056/NEJMcp022342 10.1056/NEJMcp022342 (Pubitemid 39063270)
10. JF Guest J Russ A Lenox-Smith 2005 Cost-effectiveness of venlafaxine XL compared with diazepam in the treatment of generalized anxiety disorder in the United Kingdom Eur. J. Health Econ. 6 136 145 10.1007/s10198-004-0272-z 10.1007/s10198-004-0272-z (Pubitemid 40905011)
11. TR Jorgenssen DJ Stein N Despiegel, et al. 2006 Cost-effectiveness of escitalopram compared with paroxetine in treatment of generalized anxiety disorder in the United Kingdom Ann. Pharmacother. 40 1752 1758 10.1345/aph.1H156 10.1345/aph.1H156 (Pubitemid 44544872)
12. Baldinetti, F., Bandelow, B., Kasper, S., Herman, B., Nivoli, G., Van Ameringen, M., Petralia, A., Mandel, F.S.: Efficacy of pregabalin and venlafaxine-XR in generalized anxiety disorder: results of a double-blind, placebo-controlled 8-week trial. Int. Clin. Psychopharmacol. 24, 87-96 (2009)
13. Vera-Llonch, M., Brandenburg, N, Oster, G: Cost-effectiveness of pregabalin in patients with partial refractory epilepsy. Epilepsia 49(3), 431-437 (2008). doi: 10.1111/j.1528-1167.2007.01279.x (Pubitemid 351294524)
14. M Vera-Llonch E Dukes T Delea ST Wang G Oster 2006 Treatment of peripheral neuropathic pain: a dynamic simulation model Eur. J. Pain 10 3 279 285 10.1016/j.ejpain.2005.05.005 10.1016/j.ejpain.2005.05.005 (Pubitemid 43255215)
15. M Hamilton 1959 The assessment of anxiety states by rating Br. J. Med. Psychol. 32 1 50 55
16. Revicki, D., Brandenburg, M., Matza, L.S., et al.: Relationship between anxiety severity and health utility index scores in generalized anxiety disorder. Collegium of Internationale Neuro-Psycharmacologicum (CINP), Chicago, IL, USA, 9-13 July 2006
17. Morlock, R., Shah, H., Feltner, D., Brandenburg, N., Matza, L.S., Revicki, D.: Estimation of health-state utilities for patients with generalized anxiety disorder. Collegium of Internationale Neuro-Psycharmacologicum (CINP), Chicago, IL, USA, 9-13 July 2006
18. ML Feldstein 1991 Quality-of-life-adjusted survival for comparing cancer treatments. A commentary on TWiST and Q-TWiST Cancer 67 Suppl 3 851 854 10.1002/1097-0142(19910201)67:3+<851::AID-CNCR2820671417>3.0.CO;2-G 10.1002/1097-0142(19910201)67:3+<851::AID-CNCR2820671417>3.0.CO;2-G
19. TR Einarson A Arikian M Iskedjian 1997 Pharmacoeconomic analyses of venlafaxine in the treatment of major depressive disorder Pharmacoeconomics 12 2 Pt 2 286 296 10.2165/00019053-199712020-00019 10.2165/00019053-199712020-00019
20. MA Markowitz JA Mauskopf MT Halpern 1998 Cost-effectiveness model of adjunctive lamotrigine for the treatment of epilepsy Neurology 51 4 1026 1033
21. L Blais O Sheehy JM Saint-Hilaire GP Bernier P Godfroid J LeLorier 2005 Economic evaluation of levetiracetam as an add-on therapy in patients with refractory epilepsy Pharmacoeconomics 23 5 493 503 10.2165/00019053-200523050- 00008 10.2165/00019053-200523050-00008 (Pubitemid 40994137)
22. GW Wan HF Zhang MA Tedeschi D Hackett 2006 Estimation of symptom-free days in generalized anxiety disorders Curr. Med. Res. Opin. 22 3 587 591 10.1185/030079906X96245 10.1185/030079906X96245
23. SG Ball A Kuhn D Wall, et al. 2005 Selective serotonin reuptake inhibitor treatment for generalized anxiety disorder: a double-blind, prospective comparison between paroxetine and sertraline J. Clin. Psychiatr. 66 94 99 10.4088/JCP.v66n0113
24. K Rickels R Zaninelli J McCafferty K Bellew M Iyengar D Sheehan 2003 Paroxetine treatment of generalized anxiety disorder: a double-blind, placebo-controlled study Am. J. Psychiatr. 160 749 756 10.1176/appi.ajp.160.4. 749 10.1176/appi.ajp.160.4.749 (Pubitemid 41079609)
25. MH Pollack R Zaninelli A Goddard, et al. 2001 Paroxetine in the treatment of generalized anxiety disorder: results of a placebo-controlled, flexible-dosage trial J. Clin. Psychiatr. 62 350 357 (Pubitemid 32545557)
26. P Rocca V Fonzo M Scotta E Zanalda L Ravizza 1997 Paroxetine efficacy in the treatment of generalized anxiety disorder Acta Psychiatr. Scand. 95 444 450 10.1111/j.1600-0447.1997.tb09660.x 10.1111/j.1600-0447.1997.tb09660.x
27. P Dolan 1997 Modeling valuations for EuroQol health states Med. Care 35 11 1095 1108 10.1097/00005650-199711000-00002 10.1097/00005650-199711000-00002
28. J Rovira G Albarracin L Salvador-Carulla J Rejas 2007 Cost and burden of illness of generalized anxiety disorder (GAD): a Spanish perspective from the primary health-care setting (The ANCORA Study) Eur. J. Neuropsychopharmacol. 17 Suppl 4 S507 S508 10.1016/S0924-977X(07)70781-2 10.1016/S0924-977X(07)70781-2
29. Catalogo del Consejo General de Colegios Farmaceuticos: Base de datos de medicamentos. Consejo General de Colegios Oficiales de Farmaceuticos. http://www.portalfarma.com/home.nsf (accessed March 2008)
30. Oblikue Consulting 2007. http://www.oblikue.com/bddcostes (accessed March 2008)
31. B Craig M Black P Sendi 2000 Uncertainty in decision models analyzing cost-effectiveness Med. Decis. Making 20 1 135 137 10.1177/0272989X0002000118 10.1177/0272989X0002000118
32. E Halpern M Weinstein M Hunink GS Gazelle 2000 Representing first- and second-order uncertainties by Monte Carlo simulation for groups of patients Med. Decis. Making 20 3 314 322 10.1177/0272989X0002000308 10.1177/ 0272989X0002000308
33. JA Sacristan J Oliva J Del Llano L Prieto JL Pinto 2002 Que es una tecnologia sanitaria eficiente en Espana? Gac. Sanit. 16 4 334 343